Clinical Trial Update: A Long-Term, Open-Label, Study on Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

This update notes the termination of a long-term, open-label schizophrenia trial conducted in Phase 2/Phase 3 by Eli Lilly and Company; no results are provided …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: TERMINATED